· Favorable Phase I profile and encouraging weight loss signals of potential first-in-class triple agonist BI 3034701 supports further development
Gubra partner Boehringer Ingelheim today announced the advancement of BI 3034701, its long-acting potential first-in-class triple-agonist peptide, in development for the treatment of obesity. This milestone reflects Boehringer's strategy to address the global burden of obesity and its interconnected cardiovascular, renal, metabolic (CRM) complications.
"We are very pleased to see Boehringer Ingelheim advancing this first-in-class triple-agonist to the next phase of clinical development. It builds on our joint ambition to develop novel assets for the treatment of obesity and related diseases", said Markus Rohrwild, CEO of Gubra.
The unmet medical need is high and more than one billion people worldwide live with obesity, a complex, chronic disease associated with heightened risk of liver, cardiovascular, renal and metabolic complications.
Progression follows the completion of a randomized, placebo-controlled Phase I study in healthy volunteers and people with overweight/obesity, where BI 3034701 demonstrated a favorable safety and tolerability profile and showed encouraging weight-loss.
BI 3034701 was developed in cooperation with Gubra. Boehringer Ingelheim is solely responsible for further development and global commercialization of BI 3034701. The progression of this asset further expands Boehringer Ingelheim's patient-centric CRM pipeline portfolio.
As part of the license agreement, Gubra is entitled to receive potential success-based development, regulatory and commercialization milestones and royalties.
Contacts at Gubra
Media: Sofia Pitt Boserup (sbo@gubra.dk, +45 4188 9586)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Emma Jappe Lange (ejl@gubra.dk, +45 5361 6755)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra's activities are focused on the early stages of drug development and are organized in two main business units - Biotech (D&P) and CRO services. The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around EUR 350 million) in the first 9 months of 2025. See www.gubra.dk for more information.
This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-08 08:00 CET.
